Who
Jerrold B. Grossman
Director
Company insider
Files Form 4 as: Director, ADMA Biologics.
In numbers
- Trades disclosed
- 70
- Buys
- 21
- Sells
- 2
- Bought
- $2.7M
- Sold
- $2.6M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 13 Feb 2012
- Last trade
- 27 May 2026
- Last filed
- 28 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 May 2026filed 28 May 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Bought | $51K6,400 at $7.91 | filing |
| 27 May 2026filed 28 May 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Bought | $51K6,400 at $7.91 | filing |
| 12 May 2026filed 14 May 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Bought | $100K12,500 at $8.01 | filing |
| 12 May 2026filed 14 May 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Bought | $100K12,500 at $8.01 | filing |
| 11 May 2026filed 12 May 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Bought | $100K12,500 at $8.01 | filing |
| 11 May 2026filed 12 May 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Bought | $100K12,500 at $8.01 | filing |
| 9 Feb 2026filed 11 Feb 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Code A | —10,690 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,730 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,730 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Code A | —10,690 at $0.00 | filing |
| 9 Jun 2025filed 10 Jun 2025 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 9 Jun 2025filed 10 Jun 2025 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Code M | $50K10,000 at $5.00 | filing |
| 9 Jun 2025filed 10 Jun 2025 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Sold | $213K10,000 at $21.31 | filing |
| 19 Feb 2025filed 21 Feb 2025 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,279 at $0.00 | filing |
| 19 Feb 2025filed 21 Feb 2025 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Code A | —10,889 at $0.00 | filing |
| 29 Aug 2024filed 30 Aug 2024 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | $435K118,861 at $3.66 | filing |
| 29 Aug 2024filed 30 Aug 2024 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | $54K9,000 at $5.96 | filing |
| 29 Aug 2024filed 30 Aug 2024 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | $97K9,000 at $10.80 | filing |
| 29 Aug 2024filed 30 Aug 2024 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Code M | $435K118,861 at $3.66 | filing |
| 29 Aug 2024filed 30 Aug 2024 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Code M | $54K9,000 at $5.96 | filing |
News
Arcturus Therapeutics (NASDAQ:ARCT) & ADMA Biologics (NASDAQ:ADMA) Head-To-Head SurveyADMA · dailypolitical.com · 18 Oct 2026Analyzing Anika Therapeutics (NASDAQ:ANIK) & ADMA Biologics (NASDAQ:ADMA)ADMA · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Jerrold B. Grossman; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.